Clinical trial

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

NCT02586025

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention FEC Chemotherapy Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Surgery Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxel View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumab View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-03-14

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

FEC ChemotherapyDRUG

SurgeryPROCEDURE

DocetaxelDRUG · verified · RxNorm: docetaxel

PertuzumabDRUG · verified · RxNorm: pertuzumab

PlaceboDRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

TaipeiTaiwan2 ShanghaiChina2 GuangzhouChina2 ChangchunChina2 SeoulSouth Korea1 BeijingChina1 TaichungTaiwan1 BangkokThailand1 DaeguSouth Korea1 NanjingChina1 JinanChina1 Gyeonggi-doSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02586025 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.